AI Verdict
IDYA has stronger fundamentals based on our AI analysis.
IGC vs IDYA Fundamental Comparison
| Metric | IGC | IDYA |
|---|---|---|
| Revenue | $519,000.0 | $218.7M |
| Net Income | $-3.4M | $-113.7M |
| Net Margin | -659.0% | -52.0% |
| ROE | -42.3% | -11.1% |
| ROA | -35.1% | -10.2% |
| Current Ratio | 1.32x | 11.34x |
| Debt/Equity | 0.02x | 0.00x |
| EPS | $-0.04 | $-1.28 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
IGC vs IDYA: Frequently Asked Questions
Is IGC or IDYA a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), IDYA has stronger fundamentals. IGC is rated STRONG SELL (85% confidence) while IDYA is rated BUY (72% confidence). This is not investment advice.
How does IGC compare to IDYA fundamentally?
IGC Pharma, Inc. has ROE of -42.3% vs IDEAYA Biosciences, Inc.'s -11.1%. Net margins are -659.0% vs -52.0% respectively.
Which stock pays higher dividends, IGC or IDYA?
IGC has a dividend yield of N/A or no dividend while IDYA has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in IGC or IDYA for long term?
For long-term investing, consider that IGC has STRONG SELL rating with 85% confidence, while IDYA has BUY rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about IGC vs IDYA?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For IGC vs IDYA, the AI consensus favors IDYA based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.